<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02469857</url>
  </required_header>
  <id_info>
    <org_study_id>ATB-202</org_study_id>
    <nct_id>NCT02469857</nct_id>
  </id_info>
  <brief_title>Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections</brief_title>
  <acronym>ACCUTE</acronym>
  <official_title>Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study of AB103 as Compared to Placebo in Patients With Necrotizing Soft Tissue Infections. ACCUTE (AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atox Bio Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomedical Advanced Research and Development Authority</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Atox Bio Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether AB103 is safe and effective in the&#xD;
      treatment of patients with necrotizing soft tissue infections (NSTI) receiving standard of&#xD;
      care therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary hypothesis of this study is that in addition to standard of care treatment (which&#xD;
      includes surgical intervention, antimicrobial therapy and critical care support for organ&#xD;
      dysfunction or failure), AB103 will demonstrate a clinically significant treatment benefit&#xD;
      over placebo.&#xD;
&#xD;
      This hypothesis will be addressed by measuring the effect of AB103 on a composite of clinical&#xD;
      parameters associated with the disease course of patients with NSTI, using a responder&#xD;
      analysis. A responding patient must meet all 5 parameters of the composite clinical success&#xD;
      end point, while a non-responding patient can fail by not meeting any one of the parameters.&#xD;
      These analyses are designed to demonstrate that in addition to being safe, one dose of 0.5&#xD;
      mg/kg of AB103 will:&#xD;
&#xD;
      Improve systemic signs of the infection by improving organ function of patients compared to&#xD;
      placebo as measured by:&#xD;
&#xD;
        -  Survival at Day 28&#xD;
&#xD;
        -  Modified SOFA (mSOFA) score on Day 14 and change from baseline to Day 14 ≥ 3. A Day 14&#xD;
           mSOFA score of ≤1 and a change from baseline (pre-treatment) to Day 14 ≥3 will be&#xD;
           required for a patient to achieve the primary composite clinical success endpoint&#xD;
           (NICCE)&#xD;
&#xD;
      Improve the local signs of the infection, as measured by:&#xD;
&#xD;
        -  Reduced number of debridements, counted to Day 14. No more than 3 debridements to Day 14&#xD;
           will be required for a patient to achieve composite clinical success&#xD;
&#xD;
        -  No amputation after the first debridement (amputation on the first debridement is not&#xD;
           considered a failure). A patient will be required to have had no amputations done after&#xD;
           the first surgical procedure in order to achieve composite clinical success.&#xD;
&#xD;
           290 patients will be recruited into the study and randomized to receive either 0.5 mg/kg&#xD;
           AB103 or placebo in a 1:1 ratio. Randomization will be stratified within center by the&#xD;
           diagnosis of Fournier's Gangrene and mSOFA score category (3-4 vs &gt;4) at screening. The&#xD;
           study will be conducted with interim analyses for futility at 100 patients and safety&#xD;
           monitored by an independent Data Monitoring Board at regular planned intervals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2015</start_date>
  <completion_date type="Actual">October 18, 2019</completion_date>
  <primary_completion_date type="Actual">August 18, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Achieving Necrotizing Infections Clinical Composite Endpoint (NICCE)</measure>
    <time_frame>28 days</time_frame>
    <description>NICCE was made up of the following 5 components, all of which had to be met to successfully achieve the primary outcome measure (i.e., a &quot;responder&quot;): (i) Alive at Day 28, (ii) ≤ 3 debridements through Day 14, (iii) No amputation performed after the first debridement, (iv) Day 14 modified Sequential Organ Failure Assessment (mSOFA) score ≤ 1, and (v) Reduction of ≥ 3 mSOFA score points between Baseline and Day 14. This analysis compared responders in the reltecimod group versus responders in the placebo group.&#xD;
Modified Sequential Organ Failure Assessment (mSOFA) total scores range from 0 to 20, with higher scores reflecting a worse clinical status or outcome. An mSOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With One or More Adverse Events (AEs)</measure>
    <time_frame>28 days</time_frame>
    <description>Number of Patients With One or More Adverse Events (AEs). Serious Adverse Events (SAEs) are included in this outcome measure since SAEs are a subset of AEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With One or More Serious Adverse Events (SAEs)</measure>
    <time_frame>28 days</time_frame>
    <description>Number of Patients with One or More Serious Adverse Events (SAEs) During the Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With One or More Secondary Infections</measure>
    <time_frame>28 days</time_frame>
    <description>Number of Patients with One or More Secondary Infections During the Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Achieving Day 14 Modified Sequential Organ Failure Assessment (mSOFA) Score of 0 or 1</measure>
    <time_frame>14 days</time_frame>
    <description>Modified Sequential Organ Failure Assessment (mSOFA) total scores range from 0 to 20, with higher scores reflecting a worse clinical status or outcome. An mSOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit (ICU)-Free Days</measure>
    <time_frame>28 days</time_frame>
    <description>ICU-free days refers to the number of days a patient did not spend time in the ICU through Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free Days</measure>
    <time_frame>28 days</time_frame>
    <description>Ventilator-free days refers to the number of days a patient was not on a ventilator through Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor-free Days</measure>
    <time_frame>28 days</time_frame>
    <description>Vasopressor-free days refers to the number of days a patient did not receive a vasopressor through Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Days</measure>
    <time_frame>90 days or until end of follow up</time_frame>
    <description>Hospital days refers to the number of days a patient spent time in the hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With a More Favorable or Less Favorable Hospital Discharge Location</measure>
    <time_frame>90 days</time_frame>
    <description>Number of patients with more favorable discharge location (home or rehabilitation facility) or less favorable discharge location (skilled nursing facility, another acute care facility, death, other)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Deaths From Day 0 Through Day 90</measure>
    <time_frame>90 days</time_frame>
    <description>The number of deaths occurring from Study Day 0 through Study Day 90</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Deaths After Day 14 Through Day 90</measure>
    <time_frame>76 days (after Day 14 through Day 90)</time_frame>
    <description>Number of deaths after Study Day 14 through Study Day 90</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Deaths From Day 0 Through Day 90 Among Patients With a Screening mSOFA Score of at Least 5</measure>
    <time_frame>90 days</time_frame>
    <description>Number and percentage of patients with a Screening mSOFA score of at least 5 who were alive on Study Day 0 and subsequently died through Study Day 90.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Deaths After Day 14 Through Day 90 Among Patients With a Screening mSOFA Score of at Least 5</measure>
    <time_frame>76 days (after Day 14 through Day 90)</time_frame>
    <description>Number and percentage of patients with a Screening mSOFA score of at least 5 who were alive on Study Day 14 and subsequently died through Study Day 90.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Deaths From Day 0 Through Day 90 Among Patients With Baseline Cardiovascular Failure (Shock)</measure>
    <time_frame>90 days</time_frame>
    <description>Number and percentage of patients with baseline cardiovascular failure (shock) who died through Study Day 90.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Deaths After Day 14 Through Day 90 Among Patients With Baseline Cardiovascular Failure (Shock)</measure>
    <time_frame>76 days (after Day 14 through Day 90)</time_frame>
    <description>Number and percentage of patients with baseline cardiovascular failure (shock) who were alive on Study Day 14 and subsequently died through Study Day 90.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients With a Screening Modified Sequential Organ Failure Assessment (mSOFA) Score of at Least 5 Who Achieved NICCE</measure>
    <time_frame>28 days</time_frame>
    <description>NICCE was made up of the following 5 components, all of which had to be met to successfully achieve the primary outcome measure: (i) Alive at Day 28, (ii) ≤ 3 debridements through Day 14, (iii) No amputation performed after the first debridement, (iv) Day 14 modified Sequential Organ Failure Assessment (mSOFA) score ≤ 1, and (v) Reduction of ≥ 3 mSOFA score points between Baseline and Day 14.&#xD;
Modified Sequential Organ Failure Assessment (mSOFA) total scores range from 0 to 20, with higher scores reflecting a worse clinical status or outcome. An mSOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients With a Screening mSOFA Score of at Least 5 Who Achieved Day 14 Modified Sequential Organ Failure Assessment (mSOFA) Score of 0 or 1</measure>
    <time_frame>14 days</time_frame>
    <description>Modified Sequential Organ Failure Assessment (mSOFA) total scores range from 0 to 20, with higher scores reflecting a worse clinical status or outcome. An mSOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients With Baseline Cardiovascular Failure (Shock) Who Achieved NICCE</measure>
    <time_frame>28 days</time_frame>
    <description>NICCE was made up of the following 5 components, all of which had to be met to successfully achieve the primary outcome measure: (i) Alive at Day 28, (ii) ≤ 3 debridements through Day 14, (iii) No amputation performed after the first debridement, (iv) Day 14 modified Sequential Organ Failure Assessment (mSOFA) score ≤ 1, and (v) Reduction of ≥ 3 mSOFA score points between Baseline and Day 14.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients With Baseline Cardiovascular Failure (Shock) Who Achieved Day 14 Modified Sequential Organ Failure Assessment (mSOFA) Score of 0 or 1</measure>
    <time_frame>14 days</time_frame>
    <description>Modified Sequential Organ Failure Assessment (mSOFA) total scores range from 0 to 20, with higher scores reflecting a worse clinical status or outcome. An mSOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">290</enrollment>
  <condition>Necrotizing Soft Tissue Infections</condition>
  <condition>Necrotizing Fasciitis</condition>
  <condition>Fournier's Gangrene</condition>
  <arm_group>
    <arm_group_label>AB103 0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AB103 0.5 mg/kg, IV, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCl 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl 0.9%, IV, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB103 0.5 mg/kg</intervention_name>
    <arm_group_label>AB103 0.5 mg/kg</arm_group_label>
    <other_name>reltecimod</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NaCl 0.9%</intervention_name>
    <arm_group_label>NaCl 0.9%</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Surgical confirmation of NSTI by attending surgeon;&#xD;
&#xD;
          2. mSOFA score ≥3 (in any one or combination of the 5 major components of SOFA score with&#xD;
             one organ component having a score of at least 2: cardiovascular, respiratory, renal,&#xD;
             coagulation, CNS), measured as close as possible to the first debridement;&#xD;
&#xD;
          3. IV drug administration within 6 hours from the clinical diagnosis and the decision at&#xD;
             the study site, to have an urgent surgical exploration and debridement (drug should&#xD;
             not be administered until surgical confirmation is established);&#xD;
&#xD;
          4. If a woman is of childbearing potential, she must consistently use an acceptable&#xD;
             method of contraception from baseline through Day 28;&#xD;
&#xD;
          5. If a male patient's sexual partner is of childbearing potential, the male patient must&#xD;
             acknowledge that they will consistently use an acceptable method of contraception&#xD;
             (defined above) from baseline through Day 28.&#xD;
&#xD;
          6. Signed and dated informed consent (ICF) as defined by the Institutional Review Board&#xD;
             (IRB) and, if applicable, California Bill of Rights. If patient is unable to&#xD;
             comprehend or sign the ICF, patient's legally acceptable representative may sign the&#xD;
             ICF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. BMI&gt;51;&#xD;
&#xD;
          2. Patient who has been operated at least once for the current NSTI infection and had a&#xD;
             curative deep tissue debridement;&#xD;
&#xD;
          3. Patients with overt peripheral vascular disease in the involved area ;&#xD;
&#xD;
          4. Diabetic patients with peripheral vascular disease who present with below the ankle&#xD;
             infection;&#xD;
&#xD;
          5. Removed deep vein thrombosis (DVT) in area of NSTI as an exclusion criteria&#xD;
&#xD;
          6. Patient with burn wounds;&#xD;
&#xD;
          7. Current condition of: (a) Inability to maintain a mean arterial pressure &gt; 50 mmHg&#xD;
             and/or systolic blood pressure &gt; 70 mmHg for at least 1 hour prior to screening&#xD;
             despite the presence of vasopressors and IV fluids or (b) a patient with respiratory&#xD;
             failure such that an SaO2 of 80% cannot be achieved or (c) a patient with refractory&#xD;
             coagulopathy (INR &gt;5) or thrombocytopenia (platelet count &lt;20,000) that does not&#xD;
             partially correct with administration of appropriate factors or blood products;&#xD;
&#xD;
          8. Chronic neurological impairment that leads to a neuro mSOFA component ≥2;&#xD;
&#xD;
          9. Recent cerebrovascular accident in the last 3 months;&#xD;
&#xD;
         10. Patients with cardiac arrest requiring cardiopulmonary resuscitation within the past&#xD;
             30 days;&#xD;
&#xD;
         11. Patient is not expected to survive throughout 28 days of study due to underlying&#xD;
             medical condition, such as poorly controlled neoplasm;&#xD;
&#xD;
         12. Patient or patient's family are not committed to aggressive management of the&#xD;
             patient's condition;&#xD;
&#xD;
         13. Any concurrent medical condition, which in the opinion of the Investigator, may&#xD;
             compromise the safety of the patient or the objectives of the study or the patient&#xD;
             will not benefit from treatment such as:&#xD;
&#xD;
               -  Congestive heart failure (CHF){ New York Heart Association (NYHA) class III-IV}&#xD;
&#xD;
               -  Severe chronic pulmonary obstructive disease (COPD)&#xD;
&#xD;
               -  Liver dysfunction {Childs-Pugh class C}&#xD;
&#xD;
               -  Immunosuppression (see Appendix F, Section 15.6 for list of excluded&#xD;
                  immunosuppressive medications)&#xD;
&#xD;
               -  Neutropenia &lt; 1,000 cells/mm3not due to the underlying infection&#xD;
&#xD;
               -  Idiopathic Thrombocytopenia Purpura&#xD;
&#xD;
               -  Receiving or about to receive chemotherapy or biologic anti-cancer treatment&#xD;
                  although hormonal manipulation therapies for breast and prostate malignancies are&#xD;
                  permitted&#xD;
&#xD;
               -  Hematological and lymphatic malignancies in the last 5 years;&#xD;
&#xD;
         14. Known HIV infection with CD4 (cluster of differentiation 4) count &lt; 200 cells/mm3 or &lt;&#xD;
             14% of all lymphocytes;&#xD;
&#xD;
         15. Patients with known chronic kidney disease (documented pre-illness creatinine value(s)&#xD;
             ≥2.0) or patients receiving renal replacement therapy for chronic kidney disease;&#xD;
&#xD;
         16. Patients that are treated with continuous hemofiltration (e.g. Continuous Veno-Venous&#xD;
             Hemofiltration) for acute kidney dysfunction, not due to NSTI, starting prior to study&#xD;
             drug administration;&#xD;
&#xD;
         17. Pregnant or lactating women;&#xD;
&#xD;
         18. Previous enrollment in a clinical trial involving investigational drug or a medical&#xD;
             device within 30 days;&#xD;
&#xD;
         19. Previous enrollment in this protocol, ATB-202 or the Phase 2 trial of AB103, ATB-201.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wayne M Dankner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Atox Bio Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eileen M Bulger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harborview Injury Prevention and Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maricopa Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner University Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>24857</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCH-Memorial Health System</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Health Shands Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryder Trauma Center/Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University at Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta University Health</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospital and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady of the Lake Regional Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baton Rouge General Hospital</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU Health Science Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland R Adams Cowley Shock Trauma Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University-Detroit Receiving Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University-Sinai Grace Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Southdale Hospital</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center-Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Health System, Inc.</name>
      <address>
        <city>Trenton</city>
        <state>New Jersey</state>
        <zip>98638</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erie County Medical Center-Affliate of SUNYat Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staten Island University Hospital-Northwell Health</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center (UCMC)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The MetroHealth System</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wright State University &amp; Premier Health Clinical Trials Research Alliance</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Elizabeth Youngstown Hospital</name>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <zip>44501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Emanuel Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's University Health Network</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Pennsylvania State University and The Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Trauma Center at PENN</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center at El Paso</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Peter Smith Health Network</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine-Ben Taub Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White Medical Center</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin-Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hộpital Estaing-CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hộpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Salengro Hopital-CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy, Hôpital Central</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nimes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Source, CHR Orleans</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bulger EM, May AK, Robinson BRH, Evans DC, Henry S, Green JM, Toschlog E, Sperry JL, Fagenholz P, Martin ND, Dankner WM, Maislin G, Wilfret D, Bernard AC; ACCUTE Study Investigators. A Novel Immune Modulator for Patients With Necrotizing Soft Tissue Infections (NSTI): Results of a Multicenter, Phase 3 Randomized Controlled Trial of Reltecimod (AB 103). Ann Surg. 2020 Sep 1;272(3):469-478. doi: 10.1097/SLA.0000000000004102.</citation>
    <PMID>32657946</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 6, 2015</study_first_submitted>
  <study_first_submitted_qc>June 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <results_first_submitted>September 3, 2021</results_first_submitted>
  <results_first_submitted_qc>October 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 5, 2021</results_first_posted>
  <disposition_first_submitted>January 25, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>January 25, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 27, 2021</disposition_first_posted>
  <last_update_submitted>October 2, 2021</last_update_submitted>
  <last_update_submitted_qc>October 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AB103</keyword>
  <keyword>Necrotizing fasciitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Soft Tissue Infections</mesh_term>
    <mesh_term>Fournier Gangrene</mesh_term>
    <mesh_term>Fasciitis</mesh_term>
    <mesh_term>Fasciitis, Necrotizing</mesh_term>
    <mesh_term>Gangrene</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02469857/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02469857/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Reltecimod (AB103) 0.5 mg/kg</title>
          <description>Reltecimod 0.5 mg/kg, single IV infusion over approximately 10 minutes</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>NaCl 0.9%, single IV infusion over approximately 10 minutes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinuation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This analysis population (As Treated/Safety Analysis Set) included all randomized patients who were exposed to study drug (reltecimod or placebo), with patients analyzed according to the treatment actually received.</population>
      <group_list>
        <group group_id="B1">
          <title>Reltecimod (AB103) 0.5 mg/kg</title>
          <description>Reltecimod 0.5 mg/kg, single IV infusion over approximately 10 minutes</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>NaCl 0.9%, single IV infusion over approximately 10 minutes</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="143"/>
            <count group_id="B2" value="147"/>
            <count group_id="B3" value="290"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.4" spread="15.3"/>
                    <measurement group_id="B2" value="56.3" spread="15.0"/>
                    <measurement group_id="B3" value="54.9" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="264"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>Instead of collecting data in the categories &quot;More than one race&quot; and &quot;Unknown or Not Reported,&quot; data were collected in the categories &quot;Other&quot; and &quot;Missing.&quot; Counts of participants in these latter 2 categories were summed and included in the category of &quot;Unknown or Not Reported&quot; in this study record.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="216"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>This measure represents the two countries from which patients were enrolled into this study and received study drug (i.e., United States and France).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.4" spread="8.3"/>
                    <measurement group_id="B2" value="33.7" spread="8.3"/>
                    <measurement group_id="B3" value="32.5" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Necrotizing Soft Tissue Infection (NSTI) Diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Necrotizing Fasciitis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="191"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fournier's Gangrene</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Gas Gangrene/Myonecrosis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other NSTI</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Comorbidities</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alcohol Abuse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Modified Sequential Organ Failure Assessment (mSOFA) Score</title>
          <description>Modified Sequential Organ Failure Assessment (mSOFA) total scores range from 0 to 20, with higher scores reflecting a worse clinical status or outcome. An mSOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.6" spread="2.5"/>
                    <measurement group_id="B2" value="5.4" spread="2.2"/>
                    <measurement group_id="B3" value="5.5" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Acute Physiology And Chronic Health Evaluation II (APACHE II) Score</title>
          <description>The Acute Physiology and Chronic Health Evaluation (APACHE) Score is a severity of illness classification system. It is determined within 24 hours of admission of a patient to an intensive care unit (ICU): an integer score from 0 to 71 is computed based on several measurements (physiologic variables, age, chronic health status). Higher scores correspond to more severe disease and a greater risk of death.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.4" spread="6.8"/>
                    <measurement group_id="B2" value="16.4" spread="6.6"/>
                    <measurement group_id="B3" value="16.4" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sepsis Presentation</title>
          <description>Sepsis presentation is based on mSOFA cardiovascular and respiratory sub-score components equal to 3 or 4.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Cardiovascular Organ Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory Organ Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Acute Kidney Injury (AKI) Presentation</title>
          <description>Stages of acute kidney injury (AKI) refer to the Kidney Disease: Improving Global Outcomes (KDIGO) stages of AKI. There are 3 KDIGO stages of AKI that are based on serum creatinine or urine output. Stage 1 represents the least severity of AKI, while Stage 3 represents the greatest severity of AKI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Any AKI at Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 2 or 3 AKI at Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Achieving Necrotizing Infections Clinical Composite Endpoint (NICCE)</title>
        <description>NICCE was made up of the following 5 components, all of which had to be met to successfully achieve the primary outcome measure (i.e., a &quot;responder&quot;): (i) Alive at Day 28, (ii) ≤ 3 debridements through Day 14, (iii) No amputation performed after the first debridement, (iv) Day 14 modified Sequential Organ Failure Assessment (mSOFA) score ≤ 1, and (v) Reduction of ≥ 3 mSOFA score points between Baseline and Day 14. This analysis compared responders in the reltecimod group versus responders in the placebo group.&#xD;
Modified Sequential Organ Failure Assessment (mSOFA) total scores range from 0 to 20, with higher scores reflecting a worse clinical status or outcome. An mSOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
        <time_frame>28 days</time_frame>
        <population>The primary analysis population (modified intent-to-treat [mITT]) included all randomized patients who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification.&#xD;
A secondary analysis of the primary outcome measure utilized the United States-modified intent-to-treat (US-mITT) analysis population which consisted only of mITT patients enrolled in the United States.</population>
        <group_list>
          <group group_id="O1">
            <title>Reltecimod (AB103) 0.5 mg/kg</title>
            <description>Reltecimod 0.5 mg/kg, single IV infusion over approximately 10 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>NaCl 0.9%, single IV infusion over approximately 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Necrotizing Infections Clinical Composite Endpoint (NICCE)</title>
          <description>NICCE was made up of the following 5 components, all of which had to be met to successfully achieve the primary outcome measure (i.e., a &quot;responder&quot;): (i) Alive at Day 28, (ii) ≤ 3 debridements through Day 14, (iii) No amputation performed after the first debridement, (iv) Day 14 modified Sequential Organ Failure Assessment (mSOFA) score ≤ 1, and (v) Reduction of ≥ 3 mSOFA score points between Baseline and Day 14. This analysis compared responders in the reltecimod group versus responders in the placebo group.&#xD;
Modified Sequential Organ Failure Assessment (mSOFA) total scores range from 0 to 20, with higher scores reflecting a worse clinical status or outcome. An mSOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
          <population>The primary analysis population (modified intent-to-treat [mITT]) included all randomized patients who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification.&#xD;
A secondary analysis of the primary outcome measure utilized the United States-modified intent-to-treat (US-mITT) analysis population which consisted only of mITT patients enrolled in the United States.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>mITT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>US-mITT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis utilized the mITT analysis population.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.135</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis utilized the US-mITT analysis population.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With One or More Adverse Events (AEs)</title>
        <description>Number of Patients With One or More Adverse Events (AEs). Serious Adverse Events (SAEs) are included in this outcome measure since SAEs are a subset of AEs.</description>
        <time_frame>28 days</time_frame>
        <population>As Treated/Safety Analysis Population: all randomized patients who were exposed to study drug (active or placebo) and categorized according to the treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg, IV infusion, single dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>NaCl 0.9%, IV infusion, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With One or More Adverse Events (AEs)</title>
          <description>Number of Patients With One or More Adverse Events (AEs). Serious Adverse Events (SAEs) are included in this outcome measure since SAEs are a subset of AEs.</description>
          <population>As Treated/Safety Analysis Population: all randomized patients who were exposed to study drug (active or placebo) and categorized according to the treatment actually received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With One or More Serious Adverse Events (SAEs)</title>
        <description>Number of Patients with One or More Serious Adverse Events (SAEs) During the Study</description>
        <time_frame>28 days</time_frame>
        <population>As Treated/Safety Analysis Population: all randomized patients who were exposed to study drug (active or placebo) and categorized according to the treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg, IV infusion, single dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>NaCl 0.9%, IV infusion, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With One or More Serious Adverse Events (SAEs)</title>
          <description>Number of Patients with One or More Serious Adverse Events (SAEs) During the Study</description>
          <population>As Treated/Safety Analysis Population: all randomized patients who were exposed to study drug (active or placebo) and categorized according to the treatment actually received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With One or More Secondary Infections</title>
        <description>Number of Patients with One or More Secondary Infections During the Study</description>
        <time_frame>28 days</time_frame>
        <population>As Treated/Safety Analysis Population: all randomized patients who were exposed to study drug (active or placebo) and categorized according to the treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg, IV infusion, single dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>NaCl 0.9%, IV infusion, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With One or More Secondary Infections</title>
          <description>Number of Patients with One or More Secondary Infections During the Study</description>
          <population>As Treated/Safety Analysis Population: all randomized patients who were exposed to study drug (active or placebo) and categorized according to the treatment actually received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Achieving Day 14 Modified Sequential Organ Failure Assessment (mSOFA) Score of 0 or 1</title>
        <description>Modified Sequential Organ Failure Assessment (mSOFA) total scores range from 0 to 20, with higher scores reflecting a worse clinical status or outcome. An mSOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
        <time_frame>14 days</time_frame>
        <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France.</population>
        <group_list>
          <group group_id="O1">
            <title>Reltecimod (AB103) 0.5 mg/kg</title>
            <description>Reltecimod 0.5 mg/kg, single IV infusion over approximately 10 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>NaCl 0.9%, single IV infusion over approximately 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Day 14 Modified Sequential Organ Failure Assessment (mSOFA) Score of 0 or 1</title>
          <description>Modified Sequential Organ Failure Assessment (mSOFA) total scores range from 0 to 20, with higher scores reflecting a worse clinical status or outcome. An mSOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
          <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.069</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Care Unit (ICU)-Free Days</title>
        <description>ICU-free days refers to the number of days a patient did not spend time in the ICU through Day 28.</description>
        <time_frame>28 days</time_frame>
        <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France.</population>
        <group_list>
          <group group_id="O1">
            <title>Reltecimod (AB103) 0.5 mg/kg</title>
            <description>Reltecimod 0.5 mg/kg, single IV infusion over approximately 10 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>NaCl 0.9%, single IV infusion over approximately 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Intensive Care Unit (ICU)-Free Days</title>
          <description>ICU-free days refers to the number of days a patient did not spend time in the ICU through Day 28.</description>
          <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="0" upper_limit="28"/>
                    <measurement group_id="O2" value="18.0" lower_limit="0" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.401</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilator-free Days</title>
        <description>Ventilator-free days refers to the number of days a patient was not on a ventilator through Day 28.</description>
        <time_frame>28 days</time_frame>
        <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France.</population>
        <group_list>
          <group group_id="O1">
            <title>Reltecimod (AB103) 0.5 mg/kg</title>
            <description>Reltecimod 0.5 mg/kg, single IV infusion over approximately 10 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>NaCl 0.9%, single IV infusion over approximately 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator-free Days</title>
          <description>Ventilator-free days refers to the number of days a patient was not on a ventilator through Day 28.</description>
          <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" lower_limit="0" upper_limit="28"/>
                    <measurement group_id="O2" value="21.0" lower_limit="0" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.195</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vasopressor-free Days</title>
        <description>Vasopressor-free days refers to the number of days a patient did not receive a vasopressor through Day 28.</description>
        <time_frame>28 days</time_frame>
        <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France.</population>
        <group_list>
          <group group_id="O1">
            <title>Reltecimod (AB103) 0.5 mg/kg</title>
            <description>Reltecimod 0.5 mg/kg, single IV infusion over approximately 10 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>NaCl 0.9%, single IV infusion over approximately 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Vasopressor-free Days</title>
          <description>Vasopressor-free days refers to the number of days a patient did not receive a vasopressor through Day 28.</description>
          <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="0" upper_limit="28"/>
                    <measurement group_id="O2" value="25.0" lower_limit="0" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.596</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Days</title>
        <description>Hospital days refers to the number of days a patient spent time in the hospital.</description>
        <time_frame>90 days or until end of follow up</time_frame>
        <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France.</population>
        <group_list>
          <group group_id="O1">
            <title>Reltecimod (AB103) 0.5 mg/kg</title>
            <description>Reltecimod 0.5 mg/kg, single IV infusion over approximately 10 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>NaCl 0.9%, single IV infusion over approximately 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Days</title>
          <description>Hospital days refers to the number of days a patient spent time in the hospital.</description>
          <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" lower_limit="1" upper_limit="103"/>
                    <measurement group_id="O2" value="19.5" lower_limit="2" upper_limit="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.512</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With a More Favorable or Less Favorable Hospital Discharge Location</title>
        <description>Number of patients with more favorable discharge location (home or rehabilitation facility) or less favorable discharge location (skilled nursing facility, another acute care facility, death, other)</description>
        <time_frame>90 days</time_frame>
        <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France.</population>
        <group_list>
          <group group_id="O1">
            <title>Reltecimod (AB103) 0.5 mg/kg</title>
            <description>Reltecimod 0.5 mg/kg, single IV infusion over approximately 10 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>NaCl 0.9%, single IV infusion over approximately 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a More Favorable or Less Favorable Hospital Discharge Location</title>
          <description>Number of patients with more favorable discharge location (home or rehabilitation facility) or less favorable discharge location (skilled nursing facility, another acute care facility, death, other)</description>
          <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>More Favorable Discharge Location</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Less Favorable Discharge Location</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Deaths From Day 0 Through Day 90</title>
        <description>The number of deaths occurring from Study Day 0 through Study Day 90</description>
        <time_frame>90 days</time_frame>
        <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France.</population>
        <group_list>
          <group group_id="O1">
            <title>Reltecimod (AB103) 0.5 mg/kg</title>
            <description>Reltecimod 0.5 mg/kg, single IV infusion over approximately 10 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>NaCl 0.9%, single IV infusion over approximately 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Deaths From Day 0 Through Day 90</title>
          <description>The number of deaths occurring from Study Day 0 through Study Day 90</description>
          <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.554</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Deaths After Day 14 Through Day 90</title>
        <description>Number of deaths after Study Day 14 through Study Day 90</description>
        <time_frame>76 days (after Day 14 through Day 90)</time_frame>
        <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France. Data from patients in the US-mITT population alive on Day 14 (119 reltecimod patients and 124 placebo patients) were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Reltecimod (AB103) 0.5 mg/kg</title>
            <description>Reltecimod 0.5 mg/kg, single IV infusion over approximately 10 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>NaCl 0.9%, single IV infusion over approximately 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Deaths After Day 14 Through Day 90</title>
          <description>Number of deaths after Study Day 14 through Study Day 90</description>
          <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France. Data from patients in the US-mITT population alive on Day 14 (119 reltecimod patients and 124 placebo patients) were included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.148</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Deaths From Day 0 Through Day 90 Among Patients With a Screening mSOFA Score of at Least 5</title>
        <description>Number and percentage of patients with a Screening mSOFA score of at least 5 who were alive on Study Day 0 and subsequently died through Study Day 90.</description>
        <time_frame>90 days</time_frame>
        <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France. Data from patients in the US-mITT population with a Screening mSOFA score of at least 5 were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Reltecimod (AB103) 0.5 mg/kg</title>
            <description>Reltecimod 0.5 mg/kg, single IV infusion over approximately 10 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>NaCl 0.9%, single IV infusion over approximately 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Deaths From Day 0 Through Day 90 Among Patients With a Screening mSOFA Score of at Least 5</title>
          <description>Number and percentage of patients with a Screening mSOFA score of at least 5 who were alive on Study Day 0 and subsequently died through Study Day 90.</description>
          <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France. Data from patients in the US-mITT population with a Screening mSOFA score of at least 5 were included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.736</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Deaths After Day 14 Through Day 90 Among Patients With a Screening mSOFA Score of at Least 5</title>
        <description>Number and percentage of patients with a Screening mSOFA score of at least 5 who were alive on Study Day 14 and subsequently died through Study Day 90.</description>
        <time_frame>76 days (after Day 14 through Day 90)</time_frame>
        <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France. Data from patients in the US-mITT population with a Screening mSOFA score of at least 5 who were alive on Day 14 (64 reltecimod patients and 69 placebo patients) were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Reltecimod (AB103) 0.5 mg/kg</title>
            <description>Reltecimod 0.5 mg/kg, single IV infusion over approximately 10 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>NaCl 0.9%, single IV infusion over approximately 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Deaths After Day 14 Through Day 90 Among Patients With a Screening mSOFA Score of at Least 5</title>
          <description>Number and percentage of patients with a Screening mSOFA score of at least 5 who were alive on Study Day 14 and subsequently died through Study Day 90.</description>
          <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France. Data from patients in the US-mITT population with a Screening mSOFA score of at least 5 who were alive on Day 14 (64 reltecimod patients and 69 placebo patients) were included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.093</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Deaths From Day 0 Through Day 90 Among Patients With Baseline Cardiovascular Failure (Shock)</title>
        <description>Number and percentage of patients with baseline cardiovascular failure (shock) who died through Study Day 90.</description>
        <time_frame>90 days</time_frame>
        <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France. Data from patients in the US-mITT population with baseline cardiovascular failure (i.e., shock; 75 reltecimod patients and 56 placebo patients) were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Reltecimod (AB103) 0.5 mg/kg</title>
            <description>Reltecimod 0.5 mg/kg, single IV infusion over approximately 10 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>NaCl 0.9%, single IV infusion over approximately 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Deaths From Day 0 Through Day 90 Among Patients With Baseline Cardiovascular Failure (Shock)</title>
          <description>Number and percentage of patients with baseline cardiovascular failure (shock) who died through Study Day 90.</description>
          <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France. Data from patients in the US-mITT population with baseline cardiovascular failure (i.e., shock; 75 reltecimod patients and 56 placebo patients) were included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.352</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Deaths After Day 14 Through Day 90 Among Patients With Baseline Cardiovascular Failure (Shock)</title>
        <description>Number and percentage of patients with baseline cardiovascular failure (shock) who were alive on Study Day 14 and subsequently died through Study Day 90.</description>
        <time_frame>76 days (after Day 14 through Day 90)</time_frame>
        <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France. Data from patients in the US-mITT population with baseline cardiovascular failure (i.e., shock; 63 reltecimod patients and 48 placebo patients) were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Reltecimod (AB103) 0.5 mg/kg</title>
            <description>Reltecimod 0.5 mg/kg, single IV infusion over approximately 10 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>NaCl 0.9%, single IV infusion over approximately 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Deaths After Day 14 Through Day 90 Among Patients With Baseline Cardiovascular Failure (Shock)</title>
          <description>Number and percentage of patients with baseline cardiovascular failure (shock) who were alive on Study Day 14 and subsequently died through Study Day 90.</description>
          <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France. Data from patients in the US-mITT population with baseline cardiovascular failure (i.e., shock; 63 reltecimod patients and 48 placebo patients) were included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With a Screening Modified Sequential Organ Failure Assessment (mSOFA) Score of at Least 5 Who Achieved NICCE</title>
        <description>NICCE was made up of the following 5 components, all of which had to be met to successfully achieve the primary outcome measure: (i) Alive at Day 28, (ii) ≤ 3 debridements through Day 14, (iii) No amputation performed after the first debridement, (iv) Day 14 modified Sequential Organ Failure Assessment (mSOFA) score ≤ 1, and (v) Reduction of ≥ 3 mSOFA score points between Baseline and Day 14.&#xD;
Modified Sequential Organ Failure Assessment (mSOFA) total scores range from 0 to 20, with higher scores reflecting a worse clinical status or outcome. An mSOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
        <time_frame>28 days</time_frame>
        <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France. Data from patients in the US-mITT population with a Screening mSOFA score of at least 5 (77 reltecimod patients and 79 placebo patients) were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Reltecimod (AB103) 0.5 mg/kg</title>
            <description>Reltecimod 0.5 mg/kg, single IV infusion over approximately 10 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>NaCl 0.9%, single IV infusion over approximately 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a Screening Modified Sequential Organ Failure Assessment (mSOFA) Score of at Least 5 Who Achieved NICCE</title>
          <description>NICCE was made up of the following 5 components, all of which had to be met to successfully achieve the primary outcome measure: (i) Alive at Day 28, (ii) ≤ 3 debridements through Day 14, (iii) No amputation performed after the first debridement, (iv) Day 14 modified Sequential Organ Failure Assessment (mSOFA) score ≤ 1, and (v) Reduction of ≥ 3 mSOFA score points between Baseline and Day 14.&#xD;
Modified Sequential Organ Failure Assessment (mSOFA) total scores range from 0 to 20, with higher scores reflecting a worse clinical status or outcome. An mSOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
          <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France. Data from patients in the US-mITT population with a Screening mSOFA score of at least 5 (77 reltecimod patients and 79 placebo patients) were included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With a Screening mSOFA Score of at Least 5 Who Achieved Day 14 Modified Sequential Organ Failure Assessment (mSOFA) Score of 0 or 1</title>
        <description>Modified Sequential Organ Failure Assessment (mSOFA) total scores range from 0 to 20, with higher scores reflecting a worse clinical status or outcome. An mSOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
        <time_frame>14 days</time_frame>
        <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France. Data from patients in the US-mITT population with a Screening mSOFA score of at least 5 (77 reltecimod patients and 79 placebo patients) were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Reltecimod (AB103) 0.5 mg/kg</title>
            <description>Reltecimod 0.5 mg/kg, single IV infusion over approximately 10 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>NaCl 0.9%, single IV infusion over approximately 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a Screening mSOFA Score of at Least 5 Who Achieved Day 14 Modified Sequential Organ Failure Assessment (mSOFA) Score of 0 or 1</title>
          <description>Modified Sequential Organ Failure Assessment (mSOFA) total scores range from 0 to 20, with higher scores reflecting a worse clinical status or outcome. An mSOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
          <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France. Data from patients in the US-mITT population with a Screening mSOFA score of at least 5 (77 reltecimod patients and 79 placebo patients) were included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Baseline Cardiovascular Failure (Shock) Who Achieved NICCE</title>
        <description>NICCE was made up of the following 5 components, all of which had to be met to successfully achieve the primary outcome measure: (i) Alive at Day 28, (ii) ≤ 3 debridements through Day 14, (iii) No amputation performed after the first debridement, (iv) Day 14 modified Sequential Organ Failure Assessment (mSOFA) score ≤ 1, and (v) Reduction of ≥ 3 mSOFA score points between Baseline and Day 14.</description>
        <time_frame>28 days</time_frame>
        <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France. Data from patients in the US-mITT population with baseline cardiovascular failure (i.e., shock; 75 reltecimod patients and 56 placebo patients) were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Reltecimod (AB103) 0.5 mg/kg</title>
            <description>Reltecimod 0.5 mg/kg, single IV infusion over approximately 10 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>NaCl 0.9%, single IV infusion over approximately 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Baseline Cardiovascular Failure (Shock) Who Achieved NICCE</title>
          <description>NICCE was made up of the following 5 components, all of which had to be met to successfully achieve the primary outcome measure: (i) Alive at Day 28, (ii) ≤ 3 debridements through Day 14, (iii) No amputation performed after the first debridement, (iv) Day 14 modified Sequential Organ Failure Assessment (mSOFA) score ≤ 1, and (v) Reduction of ≥ 3 mSOFA score points between Baseline and Day 14.</description>
          <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France. Data from patients in the US-mITT population with baseline cardiovascular failure (i.e., shock; 75 reltecimod patients and 56 placebo patients) were included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Baseline Cardiovascular Failure (Shock) Who Achieved Day 14 Modified Sequential Organ Failure Assessment (mSOFA) Score of 0 or 1</title>
        <description>Modified Sequential Organ Failure Assessment (mSOFA) total scores range from 0 to 20, with higher scores reflecting a worse clinical status or outcome. An mSOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
        <time_frame>14 days</time_frame>
        <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France. Data from patients in the US-mITT population with baseline cardiovascular failure (i.e., shock; 75 reltecimod patients and 56 placebo patients) were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Reltecimod (AB103) 0.5 mg/kg</title>
            <description>Reltecimod 0.5 mg/kg, single IV infusion over approximately 10 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>NaCl 0.9%, single IV infusion over approximately 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Baseline Cardiovascular Failure (Shock) Who Achieved Day 14 Modified Sequential Organ Failure Assessment (mSOFA) Score of 0 or 1</title>
          <description>Modified Sequential Organ Failure Assessment (mSOFA) total scores range from 0 to 20, with higher scores reflecting a worse clinical status or outcome. An mSOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
          <population>The United States modified intent-to-treat (US-mITT) population included all randomized patients in the United States who were exposed to study drug and who had a definitive diagnosis of NSTI based on surgical verification. This population does not include 17 patients randomized in France. Data from patients in the US-mITT population with baseline cardiovascular failure (i.e., shock; 75 reltecimod patients and 56 placebo patients) were included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event (AE) data were collected from study drug administration through the Day 28 visit. Data associated with deaths and study drug-related serious adverse events (SAEs) were collected from study drug administration though the Day 90 visit.</time_frame>
      <desc>Safety data obtained during study visits associated with Study Days 1, 2, 3, 7, 10, 14, 21, and 28 were systematically assessed throughout the study. In addition, data from spontaneously reported AEs were included in safety assessments. Data associated with deaths and study drug-related serious adverse events (SAEs) were collected from study drug administration though the Day 90 visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Reltecimod (AB103) 0.5 mg/kg</title>
          <description>Reltecimod (AB103) 0.5 mg/kg, single IV infusion over approximately 10 minutes</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>NaCl 0.9%, single IV infusion over approximately 10 minutes</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Coronary artery perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pulmonary valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal compartment syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Organ failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Funguria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Necrotizing fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Necrotizing soft tissue infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hypoglycemic coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute lung injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Bronchopleural fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin discoloration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Leg amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Peripheral ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="143"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="143"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="143"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="143"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wayne M Dankner, MD, Chief Medical Officer</name_or_title>
      <organization>Atox Bio, Ltd.</organization>
      <phone>1-919-219-6377</phone>
      <email>wayned@atoxbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

